Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Diabetes Discourse

The Potential of Immunotherapy in Type 1 Diabetes

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    Development of a combination therapy is showing significant promise in type 1 diabetes when caught in the early stages. What are some immuno-therapies currently being evaluated for treating type 1 diabetes? Join host Dr. Steven Edelman and his guest, director of the Center for Type 1 Diabetes Research at the La Jolla Institute for Allergy and Immunology, Dr. Matthias von Herrath, as they discuss histopathology, antigen-specific therapy, anti-CD3d antibodies and more.

Recommended
Details
Presenters
Comments
  • Overview

    Development of a combination therapy is showing significant promise in type 1 diabetes when caught in the early stages. What are some immuno-therapies currently being evaluated for treating type 1 diabetes? Join host Dr. Steven Edelman and his guest, director of the Center for Type 1 Diabetes Research at the La Jolla Institute for Allergy and Immunology, Dr. Matthias von Herrath, as they discuss histopathology, antigen-specific therapy, anti-CD3d antibodies and more.

Schedule23 Oct 2024